Mr Robert Klupacs was inducted on 1 March 2023 as a designee of new corporate member, Bionics Institute. Robert will be a member of the Central 2 Group.
Robert has been Chief Executive Officer of the Bionics Institute since May 2017. He has over thirty years of international corporate experience in technology development, mainly in the fields of medical technologies and biotechnology, with a particular focus on healthcare.
Robert is scientifically trained in pharmacology and biochemistry.
He is also an Australian-registered patent attorney with extensive experience in private and publicly traded companies as well as academia.
Robert’s broad career includes appointments as Director of Intellectual Property at AMRAD, COO of the Monash Institute of Reproduction and Development, CEO of Singapore-based ES Cell International, Managing Director and CEO of ASX-listed Circadian Technologies Ltd, and Executive Chairman of Bionic Vision Technologies Pty Ltd.
He has served as a non-executive director for several early-stage companies and Co-operative Research Centres and is currently a non-executive director of Bionic Vision Technologies Pty Ltd and ASX-listed Bio-Gene Technology Limited.
Prior to accepting the CEO role at the Bionics Institute, he founded and operated the technology development advisory company Magdajano Pty Ltd.
Robert is a founder of 27 companies in Australia and Singapore and was previously a member of the Pharmaceutical Industry Group and the Victorian Biotechnology Advisory Committee.
Robert was inducted as a Fellow of the Australian Academy of Science and Engineering in November 2020.
https://www.bionicsinstitute.org/
